Sarcoidosis of the Nervous System

Allan Krumholz, Barney Stern

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Neurologic manifestations occur in more than 5 percent of patients with sarcoidosis and may be the presenting feature. Neurosarcoidosis can manifest in many ways including by cranial neuropathy, aseptic meningitis, mass lesions, encephalopathy, vasculopathy, seizures, hypothalamic-pituitary disorders, hydrocephalus, myelopathy, peripheral neuropathy, and myopathy. Because its etiology is unknown, its neurologic manifestations are so diverse, and its diagnosis cannot be confirmed readily by laboratory tests, neurosarcoidosis poses many clinical challenges. Its diagnosis is usually based on the identification of characteristic neurologic findings in an individual with proven systemic sarcoidosis. Although corticosteroids are the basis of treatment, they are not always successful and have potentially serious side effects. Moreover, some patients with neurosarcoidosis are refractory to conventional therapy, and approximately 5 percent die. Optimal management of patients with neurosarcoidosis benefits from an understanding of the broad clinical spectrum of the disorder, the ways to best confirm a diagnosis, and the full range of treatment options, including the use of alternative immunotherapies.

Original languageEnglish (US)
Title of host publicationAminoff's Neurology and General Medicine
Subtitle of host publicationFifth Edition
PublisherElsevier Inc.
Pages985-1002
Number of pages18
ISBN (Print)9780124077102
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Neurologic Manifestations
Sarcoidosis
Pituitary Diseases
Aseptic Meningitis
Cranial Nerve Diseases
Spinal Cord Diseases
Brain Diseases
Peripheral Nervous System Diseases
Muscular Diseases
Hydrocephalus
Immunotherapy
Adrenal Cortex Hormones
Seizures
Therapeutics
Neurosarcoidosis

Keywords

  • Cranial neuropathies
  • CSF
  • Immunosuppression
  • Inflammation
  • MRI
  • Neurosarcoidosis
  • Sarcoidosis
  • Systemic disease

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Cite this

Krumholz, A., & Stern, B. (2014). Sarcoidosis of the Nervous System. In Aminoff's Neurology and General Medicine: Fifth Edition (pp. 985-1002). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-407710-2.00049-7

Sarcoidosis of the Nervous System. / Krumholz, Allan; Stern, Barney.

Aminoff's Neurology and General Medicine: Fifth Edition. Elsevier Inc., 2014. p. 985-1002.

Research output: Chapter in Book/Report/Conference proceedingChapter

Krumholz, A & Stern, B 2014, Sarcoidosis of the Nervous System. in Aminoff's Neurology and General Medicine: Fifth Edition. Elsevier Inc., pp. 985-1002. https://doi.org/10.1016/B978-0-12-407710-2.00049-7
Krumholz A, Stern B. Sarcoidosis of the Nervous System. In Aminoff's Neurology and General Medicine: Fifth Edition. Elsevier Inc. 2014. p. 985-1002 https://doi.org/10.1016/B978-0-12-407710-2.00049-7
Krumholz, Allan ; Stern, Barney. / Sarcoidosis of the Nervous System. Aminoff's Neurology and General Medicine: Fifth Edition. Elsevier Inc., 2014. pp. 985-1002
@inbook{855c68d30a02459881ccee62ce49bf49,
title = "Sarcoidosis of the Nervous System",
abstract = "Neurologic manifestations occur in more than 5 percent of patients with sarcoidosis and may be the presenting feature. Neurosarcoidosis can manifest in many ways including by cranial neuropathy, aseptic meningitis, mass lesions, encephalopathy, vasculopathy, seizures, hypothalamic-pituitary disorders, hydrocephalus, myelopathy, peripheral neuropathy, and myopathy. Because its etiology is unknown, its neurologic manifestations are so diverse, and its diagnosis cannot be confirmed readily by laboratory tests, neurosarcoidosis poses many clinical challenges. Its diagnosis is usually based on the identification of characteristic neurologic findings in an individual with proven systemic sarcoidosis. Although corticosteroids are the basis of treatment, they are not always successful and have potentially serious side effects. Moreover, some patients with neurosarcoidosis are refractory to conventional therapy, and approximately 5 percent die. Optimal management of patients with neurosarcoidosis benefits from an understanding of the broad clinical spectrum of the disorder, the ways to best confirm a diagnosis, and the full range of treatment options, including the use of alternative immunotherapies.",
keywords = "Cranial neuropathies, CSF, Immunosuppression, Inflammation, MRI, Neurosarcoidosis, Sarcoidosis, Systemic disease",
author = "Allan Krumholz and Barney Stern",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-407710-2.00049-7",
language = "English (US)",
isbn = "9780124077102",
pages = "985--1002",
booktitle = "Aminoff's Neurology and General Medicine",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Sarcoidosis of the Nervous System

AU - Krumholz, Allan

AU - Stern, Barney

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Neurologic manifestations occur in more than 5 percent of patients with sarcoidosis and may be the presenting feature. Neurosarcoidosis can manifest in many ways including by cranial neuropathy, aseptic meningitis, mass lesions, encephalopathy, vasculopathy, seizures, hypothalamic-pituitary disorders, hydrocephalus, myelopathy, peripheral neuropathy, and myopathy. Because its etiology is unknown, its neurologic manifestations are so diverse, and its diagnosis cannot be confirmed readily by laboratory tests, neurosarcoidosis poses many clinical challenges. Its diagnosis is usually based on the identification of characteristic neurologic findings in an individual with proven systemic sarcoidosis. Although corticosteroids are the basis of treatment, they are not always successful and have potentially serious side effects. Moreover, some patients with neurosarcoidosis are refractory to conventional therapy, and approximately 5 percent die. Optimal management of patients with neurosarcoidosis benefits from an understanding of the broad clinical spectrum of the disorder, the ways to best confirm a diagnosis, and the full range of treatment options, including the use of alternative immunotherapies.

AB - Neurologic manifestations occur in more than 5 percent of patients with sarcoidosis and may be the presenting feature. Neurosarcoidosis can manifest in many ways including by cranial neuropathy, aseptic meningitis, mass lesions, encephalopathy, vasculopathy, seizures, hypothalamic-pituitary disorders, hydrocephalus, myelopathy, peripheral neuropathy, and myopathy. Because its etiology is unknown, its neurologic manifestations are so diverse, and its diagnosis cannot be confirmed readily by laboratory tests, neurosarcoidosis poses many clinical challenges. Its diagnosis is usually based on the identification of characteristic neurologic findings in an individual with proven systemic sarcoidosis. Although corticosteroids are the basis of treatment, they are not always successful and have potentially serious side effects. Moreover, some patients with neurosarcoidosis are refractory to conventional therapy, and approximately 5 percent die. Optimal management of patients with neurosarcoidosis benefits from an understanding of the broad clinical spectrum of the disorder, the ways to best confirm a diagnosis, and the full range of treatment options, including the use of alternative immunotherapies.

KW - Cranial neuropathies

KW - CSF

KW - Immunosuppression

KW - Inflammation

KW - MRI

KW - Neurosarcoidosis

KW - Sarcoidosis

KW - Systemic disease

UR - http://www.scopus.com/inward/record.url?scp=84903857443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903857443&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-407710-2.00049-7

DO - 10.1016/B978-0-12-407710-2.00049-7

M3 - Chapter

AN - SCOPUS:84903857443

SN - 9780124077102

SP - 985

EP - 1002

BT - Aminoff's Neurology and General Medicine

PB - Elsevier Inc.

ER -